iuvo BioScience, a specialty CRO providing laboratory services, preclinical and clinical development services, and scientific consulting services to pharmaceutical and medical device customers, today announced it has hired Robert (Bobby) McFall, CPA, MBA, as their Director of Finance. This hire demonstrates iuvo's continued commitment to serving our clients, differentiated expertise, and investment in the business to support the company's growth trajectory.
ROCHESTER, N.Y., May 25, 2023 /PRNewswire-PRWeb/ -- iuvo BioScience, a specialty CRO providing laboratory services, preclinical and clinical development services, and scientific consulting services to pharmaceutical and medical device customers, today announced it has hired Robert (Bobby) McFall, CPA, MBA, as their Director of Finance. This hire demonstrates iuvo's continued commitment to serving our clients, differentiated expertise, and investment in the business to support the company's growth trajectory.
Bobby is a well-established Finance executive who brings years of experience in all aspects of finance and accounting, specifically in the healthcare industry. Bobby received his Bachelor of Business Administration and MBA from St Bonaventure University. As a CPA he began his career in public accounting at KPMG and then joined Carestream Health where his career progressed through a series of positions including Corporate Accounting and Financial Reporting Manager, Assistant Controller and, ultimately, Corporate Strategy & Finance Manager. In this role, Bobby also served as Chair of the Corporate Finance Committee. Bobby brings a wealth of financial expertise to iuvo as well as experience leading and supporting mergers and acquisitions.
McFall is excited to join the iuvo team, stating, "the foundation of the company is solid, and the strategic plan that has been developed for the company is impressive. I look forward to being part of the team and driving the delivery of the strategic plan as well leading the Finance team and setting the stage for long-term success."
Daniel Spasic, Board Chair of iuvo BioScience, said, "we are excited to welcome Bobby to the iuvo family. Our growth initiatives driven by the strategic plan are ambitious, and Bobby's leadership and finance skills will certainly add to our confidence in delivering against these plans. We look forward to working with Bobby and wish him all the best in this important role."
Finally, Ben Burton, CEO of iuvo BioScience, commented, "the timing could not be better for adding Bobby to our team. I look forward to working with him as a member of our Executive Committee as we forge ahead with our growth strategy. We are excited to have Bobby on-board."
About iuvo BioScience
Headquartered in Rochester, NY, iuvo BioScience is a highly specialized provider of preclinical, clinical, and consulting services to biotech and medical device customers. The company's facility features laboratories for analytical chemistry, formulation, microbiology, and toxicology, as well as an on-site AAALAC-accredited vivarium to support preclinical testing. Through the company's Oculos Clinical Research subsidiary, iuvo provides a suite of clinical trial services including clinical trial design, regulatory, biometrics, pharmacovigilance, project and site management. Under the Lumino Advisors brand, the company also has an end-to-end scientific consulting offering spanning from regulatory strategy, dossier development, preclinical and CMC consulting and strategic planning through trial execution and regulatory submission. Additional information about iuvo is available athttps:/http://www.iuvobioscience.com or follow us on LinkedIn.
Media Contact
Ben Burton, iuvo BioScience, 1 585-260-0724, [email protected]
Tim Mason, Mason Marketing llc, 585-259-0241, [email protected]
SOURCE iuvo BioScience
Share this article